- Home
- ATR vs JAZZ Comparison
ATR vs JAZZ Comparison
Compare ATR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATR
- JAZZ
- Stock Information
- Founded
- ATR 1992
- JAZZ 2003
- Country
- ATR United States
- JAZZ Ireland
- Employees
- ATR N/A
- JAZZ N/A
- Industry
- ATR Plastic Products
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ATR Industrials
- JAZZ Health Care
- Exchange
- ATR Nasdaq
- JAZZ Nasdaq
- Market Cap
- ATR 9.3B
- JAZZ 7.9B
- IPO Year
- ATR 1993
- JAZZ 2007
- Fundamental
- Price
- ATR $130.24
- JAZZ $136.58
- Analyst Decision
- ATR Strong Buy
- JAZZ Strong Buy
- Analyst Count
- ATR 5
- JAZZ 14
- Target Price
- ATR $183.80
- JAZZ $179.21
- AVG Volume (30 Days)
- ATR 404.0K
- JAZZ 758.5K
- Earning Date
- ATR 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- ATR 1.36%
- JAZZ N/A
- EPS Growth
- ATR 21.86
- JAZZ N/A
- EPS
- ATR 5.79
- JAZZ N/A
- Revenue
- ATR $3,610,693,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- ATR $4.27
- JAZZ $5.70
- Revenue Next Year
- ATR $4.93
- JAZZ $6.16
- P/E Ratio
- ATR $22.78
- JAZZ N/A
- Revenue Growth
- ATR 1.51
- JAZZ 4.52
- 52 Week Low
- ATR $129.81
- JAZZ $95.49
- 52 Week High
- ATR $178.03
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ATR 31.16
- JAZZ 63.56
- Support Level
- ATR $130.27
- JAZZ $125.79
- Resistance Level
- ATR $134.39
- JAZZ $140.39
- Average True Range (ATR)
- ATR 1.82
- JAZZ 3.18
- MACD
- ATR 0.19
- JAZZ 0.46
- Stochastic Oscillator
- ATR 4.04
- JAZZ 71.59
About ATR AptarGroup Inc.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.